DiagnoCure appoints Vice President of Marketing and National Sales



    Launch of its Previstage(TM) GCC Colorectal Staging Test on Plan

    QUEBEC CITY, June 26 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR), a life
sciences company commercializing high-value cancer diagnostic tests and
delivering laboratory services, is actively finalizing the imminent launch of
its new Previstage(TM) GCC Colorectal Cancer Staging Test planned for this
summer, and appoints Mr. Phillip Wells as Vice President, Marketing and
National Sales to drive this launch and commercial growth of the Company.
    Phillip Wells holds a Bachelor Degree from the College of Letters and
Science, at the University of California, Davis. He has 30 years of experience
in marketing in the global healthcare sector, where he held various positions
in sales management, marketing, managed care, business development and
participated in many successful product launches. Mr. Wells joined DiagnoCure
Inc. in 2007 as Senior Director of Reimbursement, where he has been
responsible for developing and implementing corporate strategies for gaining
reimbursement for the Company's high-value tests. Prior to joining DiagnoCure,
Mr. Wells worked at Hoechst Marion Roussel, CV Therapeutics and Prometheus
Laboratories where he was responsible for reimbursement policy for both
laboratory tests and pharmaceutical products.
    After successfully setting the stage for the launch of DiagnoCure's
Previstage(TM) GCC test, Mr. L. Blair Shamel, Sr. Vice President, Corporate
Development, has chosen to return to a consulting role. Since joining
DiagnoCure in 2003, Mr. Shamel has contributed to the achievement of
significant milestones for the Company. Among other contributions, he has been
instrumental in negotiating and managing the licensing agreement with         
Gen-Probe, DiagnoCure's PCA3 development and commercialization partner.
Mr. Shamel will continue to contribute to the Company's success as a
consultant to the CEO on the diagnostic industry.
    "Phillip Wells and his team will now lead the implementation of the
marketing and sales strategies with a clear set of goals to bring             
Previstage(TM) GCC to the forefront of the management of colorectal cancer",
stated John Schafer, President and CEO, "while Blair Shamel will continue to
provide DiagnoCure with his strategic consulting expertise."

    About DiagnoCure

    DiagnoCure (TSX: CUR) is a life sciences company commercializing
high-value cancer diagnostic tests and delivering laboratory services that
increase clinician and patient confidence in making critical treatment
decisions. DiagnoCure is currently preparing to launch the Previstage(TM) GCC
Colorectal Cancer Staging Test, the first GCC-based molecular test for the
management of colorectal cancer. In 2003, the Company entered into a strategic
alliance with Gen-Probe (NASDAQ:   GPRO) for the development and
commercialization of a second-generation test for PCA3, DiagnoCure's
proprietary molecular marker highly specific to prostate cancer. The test is
now available through laboratories in the U.S. using PCA3 analyte specific
reagents (ASR) from Gen-Probe, in Europe as the CE-marked PROGENSA(TM) PCA3 in
vitro assay, and in Canada. In addition to its own research, the Company
intends to acquire or in-license additional promising cancer biomarkers from
both academic and commercial institutions. For more information, visit
www.diagnocure.com.

    Forward looking statements

    This release contains forward-looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual results to
differ materially from those expected. By their very nature, forward-looking
statements are based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond DiagnoCure's
control. As a result, investors are cautioned not to place undue reliance on
these forward-looking statements. The forward-looking statements regarding the
outcome of research and development projects, clinical studies and future
revenues are based on management expectations. In addition, the reader is
referred to the applicable general risks and uncertainties described in
DiagnoCure's most recent Annual Information Form under the heading "Risk
Factors". DiagnoCure undertakes no obligation to publicly update or revise any
forward-looking statements contained herein.
    %SEDAR: 00003671EF




For further information:

For further information: Investors: Paule De Blois, Corporate Affairs,
DiagnoCure Inc., (418) 527-6100, communications@diagnocure.com; Media:
Jean-Pierre Trudel, Vice President, Jean-Pierre Trudel & Associates, (514)
347-6111, jp.trudel@videotron.ca

Organization Profile

DiagnoCure Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890